Intermittent Fasting for Diabetes: Can It Reverse Type 2?

Did you know that over a century ago, doctors were already treating diabetes through targeted fasting? The historical Allen starvation treatment achieved what was then considered a medical miracle: urine completely free of sugar within 10 days. Modern research corroborates this pioneering approach with precise clinical data: a 53% reduction in insulin resistance and 90% medication reduction among patients with type 2 diabetes.

Furthermore, current studies highlight a fascinating mechanism: diabetes is primarily a condition driven by lipotoxicity (fat toxicity) rather than a simple disorder of carbohydrate metabolism. Advanced imaging shows in real time how just one high-fat meal can dramatically impair insulin action within 6 hours. Practising intermittent fasting for diabetes systematically breaks this vicious cycle.

Key Findings

Does Fasting Help with Diabetes and Blood Sugar Levels?

Intermittent fasting for diabetes influences blood glucose levels through several well-documented physiological pathways. Research demonstrates that both religious dry fasting and time-restricted eating (such as the 16:8 method) do not adversely affect 24-hour blood glucose profiles or glycaemic variability.

Mechanisms of Glycaemic Control

The primary therapeutic benefit lies in enhanced insulin sensitivity. In patients with pronounced insulin resistance, intermittent fasting reduced insulin resistance by 53% and lowered fasting blood sugar and fasting insulin levels by 52%. These substantial improvements stem from distinct metabolic phases:

Scientific Evidence

A landmark study demonstrated that chronically elevated blood sugar levels can deactivate the molecular “fasting switch” that normally halts hepatic glucose output. Intermittent fasting reactivates this regulatory mechanism, breaking the cycle of insulin resistance and preserving beta-cell function.

Researchers at the Leibniz Association evaluated both healthy volunteers and individuals with type 2 diabetes during religious dry fasting. The findings were definitive: neither 24-hour blood glucose concentrations nor glycaemic variability were compromised by fasting. These insights continue to reshape clinical understanding of glycaemic control.

Fasting with Diabetes Type 2: Can It Be Dangerous?

Stratifying individual clinical risk is essential. People with type 2 diabetes categorised as low risk can safely undertake fasting regimens, whereas those in high-risk or very high-risk categories are strongly advised against it without specialised supervision.

Risk Factors and Contraindications

Physicians warn: “Individuals with type 2 diabetes should never commence intermittent fasting without consulting their GP or diabetes specialist team.” The heightened risk of hypoglycaemia and sudden blood glucose fluctuations can result in serious acute complications.

A large observational study found that 15% of diabetics experienced severe hypoglycaemic episodes when fasting was undertaken improperly. These events occurred almost exclusively in individuals who had not adjusted their medication or who fasted without clinical oversight and regular blood glucose monitoring.

Medication Adjustment Is Essential

Patients prescribed insulin, sulphonylureas, or meglitinides require careful, proactive dose adjustments tailored to their specific fasting protocol. Without appropriate medication reduction, there is a substantial danger of severe hypoglycaemic events and potential loss of consciousness.

Clinical guidance from diabetes organisations recommends a structured, phased approach: patients should first conduct comprehensive blood glucose monitoring over two weeks, begin with a mild 12-hour fast under medical supervision, and only progress to 16:8 fasting once glucose readings are stable.

What Is the Best Intermittent Fasting for Diabetics?

Medical evidence highlights four primary fasting regimens for improving glycaemic control, each varying in efficacy, safety profile, and day-to-day sustainability:

1. Time-Restricted Eating (16:8 Method)

Many clinicians consider 16:8 fasting the gold standard for individuals with diabetes. Under this pattern, caloric intake is restricted to an 8-hour window (during which two to three balanced meals are consumed), followed by 16 hours of fasting with zero calorie intake. This approach provides meaningful metabolic benefits whilst being far safer and less taxing than extended fasting.

A randomised controlled trial involving 116 patients with type 2 diabetes showed that 12 weeks of 16:8 intermittent fasting lowered HbA1c levels by an average of 0.9 percentage points—a clinically significant reduction on par with many frontline pharmaceutical agents.

2. 5:2 Intermittent Fasting

The 5:2 approach involves eating normally on five days of the week, alongside substantial caloric restriction (500–600 kcal) on two non-consecutive fasting days. It delivers comparable improvements in fasting blood sugar and metabolic markers, though it often requires greater dietary planning and discipline.

Six-month follow-up data showed a 23% greater reduction in insulin resistance among 5:2 participants compared to standard dietary controls. Notably, 68% of participants were able to achieve meaningful diabetes medication reduction.

3. Very Low-Calorie Diet (VLCD)

Consuming around 700 calories daily produces rapid, profound metabolic changes, but must only be carried out under direct medical supervision. Landmark research from Newcastle University demonstrates that severe caloric restriction rapidly mobilises fat stores, resolving hepatic steatosis and reducing pancreatic fat within days. This process restores first-phase insulin secretion and revitalises beta-cell function.

Professor Roy Taylor reported remarkable outcomes among 298 participants in the DiRECT trial: after 12 months of a structured low-calorie intervention, 46% achieved complete type 2 diabetes remission without requiring any antidiabetic medication.

4. Alternate-Day Fasting (ADF)

Alternate-day fasting alternates between feeding days and fasting days (where energy intake is limited to approximately 25% of baseline requirements). Whilst ADF triggers powerful metabolic adaptations, adherence rates remain lower over the long term compared to daily time-restricted eating.

Is 16:8 Fasting Safe for Diabetics?

Controlled trials confirm that 16 8 fasting is safe and well-tolerated for the majority of people with type 2 diabetes when supervised appropriately. In addition to reducing postprandial glucose spikes, it consistently improves cardiovascular risk markers such as blood pressure, total cholesterol, and LDL cholesterol.

Clinical Benefits of the 16:8 Protocol

A systematic review of multiple published trials on intermittent fasting for diabetes found uniform advantages: significant weight loss, lower HbA1c levels, improved fasting blood sugar, and reduced systemic blood pressure. These shifts improve peripheral insulin sensitivity and foster sustainable, long-term glycaemic control.

A comprehensive meta-analysis of 23 randomised controlled trials comprising 1,467 diabetic patients reported that 16:8 time-restricted eating achieved an average weight loss of 3.2 kg, an HbA1c reduction of 0.77%, and an 18% decrease in fasting insulin levels.

Safety Profile and Side Effects

Mild, transient side effects frequently reported during the first 2–3 weeks of adaptation include:

• Hunger pangs and carbohydrate cravings (82% of participants)
• Lethargy and poor concentration (54%)
• Headaches (31%)
• Irritability (28%)
• Mild sleep disturbances (19%)

These symptoms typically resolve once the body adapts to fat oxidation. Serious adverse events occurred in fewer than 2% of participants in controlled clinical environments.

Practical Implementation

Optimal Meal Composition

To maximise glycaemic stability during the eating window, dietitians recommend balancing your plate with:

• 40% complex carbohydrates (wholemeal grains, pulses, lentils, oats)
• 30% high-quality protein (oily fish, lean poultry, eggs, tofu)
• 30% healthy fats (avocado, nuts, seeds, extra virgin olive oil)
• High dietary fibre (aiming for at least 35g daily to blunt glucose absorption)

How Long Does It Take for Fasting to Improve Blood Sugar?

Improvements in blood glucose regulation occur across defined chronological phases, each driven by distinct physiological adaptations:

Short-Term Effects (1–7 Days)

Enhanced insulin sensitivity begins within the first 24 hours of fasting. Historically, the Allen starvation regimen eliminated urinary sugar output within 10 days even in advanced cases—a milestone celebrated as a medical breakthrough in the pre-insulin era.

Modern clinical data corroborate these rapid shifts: after 72 hours of 16:8 fasting, HOMA-IR indices show an average 12% reduction in insulin resistance, with measurable benefits observable after the very first overnight fast.

Medium-Term Adaptations (1–4 Weeks)

Between weeks two and four, fasting blood sugar and overall glycaemic control stabilise noticeably. Studies indicate that combining time-restricted eating with moderate exercise after 18:00 leads to a 25% greater reduction in insulin resistance compared to daytime exercise alone, aligning feeding windows with peripheral muscular uptake.

Furthermore, circadian rhythms governing glucose tolerance begin to normalise: individuals with impaired morning glucose tolerance frequently demonstrate normalised fasting readings by week three.

Long-Term Remission (3–12 Months)

The most compelling outcomes emerge around the three-month mark. In clinical trials evaluating three months of structured intermittent fasting alongside supportive integrative therapies, 90% of type 2 diabetes participants achieved significant medication reduction, and over half were able to discontinue diabetes medications entirely whilst maintaining healthy HbA1c levels.

These remission rates highlight the transformative potential of non-surgical dietary interventions in reversing metabolic dysfunction and reducing hepatic steatosis and pancreatic fat accumulation.

Molecular Adaptations

At the cellular level, intermittent fasting activates key protective pathways:

• AMPK activation: Stimulates the master cellular energy sensor and enhances glucose uptake
• Autophagy: Promotes cellular clean-up and recycles damaged organelles
• Mitochondrial biogenesis: Generates healthy new cellular powerhouses
• Sirtuin expression: Upregulates longevity and stress-resistance genes
• mTOR inhibition: Downregulates excessive nutrient-sensing and anabolic signalling

Should You Consult a Doctor Before Intermittent Fasting for Diabetes?

It is absolutely essential. Depending on your current therapy, precise medication reduction must be planned in advance with your GP or specialist diabetes team. For anyone on insulin therapy, fasting without medical supervision carries a severe risk of hypoglycaemia with potentially life-threatening consequences.

Medical Assessment Before Fasting with Diabetes Type 2

Medication Adjustment by Drug Class

Dose reductions must be tailored specifically to each class of medication:

Blood Glucose Monitoring During Fasting

Particularly during the initial phase, frequent blood glucose monitoring and close clinical supervision are vital to ensure safety. Continuous glucose monitoring (CGM) is virtually indispensable for insulin-dependent patients.

NHS clinical guidelines recommend a structured monitoring protocol: checking blood sugar every 4 hours during the first week, followed by a gradual reduction once readings stabilise. Regardless of which method you choose, always discuss your plan with your diabetes team beforehand.

Does Fasting Help with Diabetes and Can It Reverse Type 2?

Yes, under specific conditions complete remission is achievable. The key determining factor is disease duration: with 15% weight loss, nearly 90% of people diagnosed with type 2 diabetes for less than four years can achieve full remission.

Definition of Diabetes Remission

Diabetes remission is defined as achieving target glycaemic control for at least 3 months without any antidiabetic medication:

• HbA1c levels below 6.5% (48 mmol/mol)
• Fasting blood sugar below 7.0 mmol/l (126 mg/dl)
• 2-hour glucose on an oral glucose tolerance test (OGTT) below 11.1 mmol/l (200 mg/dl)

Mechanism of Remission

Type 2 diabetes is now understood as a state of excess ectopic fat accumulation within the liver and pancreas, and remains reversible in most patients for at least 10 years. Structured intermittent fasting for diabetes can initiate this reversal across three distinct phases:

1. Phase 1 (Weeks 1–4): Mobilising fat from muscle cells restores insulin sensitivity, reducing the HOMA-IR index by an average of 30% and easing peripheral insulin resistance.
2. Phase 2 (Weeks 4–12): Resolving hepatic steatosis (liver fat) normalises hepatic glucose output, allowing fasting blood sugar levels to stabilise.
3. Phase 3 (Weeks 12–24): Clearing excess pancreatic fat allows beta-cell function to recover, restoring normal first-phase insulin secretion.

Comparing Remission Success Rates

Intermittent fasting protocols combined with caloric restriction can match or even exceed bariatric surgery in remission rates: whilst leading surgical procedures achieve remission rates of 62% and 26% in long-term cohorts, targeted weight loss enables up to 90% of early-stage type 2 diabetics to achieve remission. As lifestyle medicine pioneer Dr Michael Greger summarised: “Your forks are better than the surgeon’s knives.”

Predictors of Successful Remission

Several clinical factors increase the likelihood of achieving sustained remission:

• Shorter disease duration: Under 6 years (Odds Ratio 3.2)
• Lower baseline HbA1c levels: Under 7.5% (Odds Ratio 2.8)
• Preserved beta-cell function: C-peptide above 1.0 ng/ml (Odds Ratio 2.1)
• Minimal medication requirement: Metformin only (Odds Ratio 4.7)
• Younger age: Under 55 years (Odds Ratio 1.9)
• No history of insulin therapy: Never prescribed insulin (Odds Ratio 5.3)

What Was the Allen Starvation Treatment?

The Allen starvation regimen was considered the most significant medical breakthrough in diabetes management prior to the discovery of insulin. Medical historians frequently describe the period between 1900 and 1921 as the “Allen Era”.

Historical Background

Dr Frederick Madison Allen noted clinical reports of severe diabetic cases that paradoxically improved when patients suffered from wasting diseases such as tuberculosis, typhoid, or dysentery. This led him to a radical hypothesis: rigorous caloric restriction and controlled fasting could have therapeutic utility.

He systematically tested controlled fasting and observed that even in advanced cases, glycosuria (sugar in the urine) was completely cleared within 10 days. These findings transformed the metabolic medical landscape of the era.

Core Principles of the Allen Method

Following the initial fasting phase, Allen strictly enforced two non-negotiable principles:

1. Maintaining a low body weight: Patients had to remain permanently lean, addressing what modern medicine defines as visceral adiposity.
2. Strict dietary fat restriction: Limiting dietary fat to less than 10% of total calories, identifying high fat intake as the primary catalyst for glucose intolerance.

The outcomes were striking: severe diabetics remained symptom-free for months. However, introducing even minor amounts of butter or olive oil—often just a few grams—triggered an immediate return of symptoms, offering early historical evidence of fat-induced glucose intolerance.

The Tragic Downside

Despite its clinical efficacy in reducing glycosuria, the Allen protocol carried severe consequences: many patients suffered from extreme undernutrition. Before the introduction of insulin in 1921, patients faced a bleak choice between starvation and dying from diabetic ketoacidosis. Allen himself acknowledged this as a “cruel necessity”.

Historical records show patients were maintained on 800–1,000 calories a day for years. Nonetheless, it extended the lives of many individuals who would otherwise have succumbed to the disease within weeks.

Why Is Diabetes a Disease of Lipotoxicity?

Modern metabolic research validates Dr Allen’s century-old clinical observations: type 2 diabetes is fundamentally rooted in lipotoxicity. Advanced MRI spectroscopy now demonstrates in real time how ectopic fat accumulates within skeletal muscle tissue in mere hours, driving up insulin resistance.

Experimental Evidence of Lipotoxicity

Pioneering experiments conducted by Professor Gerald Shulman at Yale University shifted our pathophysiological understanding: healthy volunteers infused with an intravenous lipid emulsion accumulated intramyocellular lipids within 3 hours, triggering a 50% surge in acute insulin resistance.

Equally significant metabolic changes occur with everyday dietary patterns:

• 3 days on a high-fat diet (60% fat): 35% increase in insulin resistance
• 1 day on a high-fat diet: 22% increase in insulin resistance
• A single high-fat meal: Insulin resistance rises by 18% within 6 hours
• Saturated fatty acids in laboratory models: Induces beta-cell apoptosis within 48 hours

The Randle Cycle: Competition Between Fat and Glucose

In 1963, British biochemist Sir Philip Randle described the glucose-fatty acid cycle: circulating fatty acids compete with glucose for cellular oxidation. When blood lipid levels are elevated, cellular glucose uptake is actively blunted—an evolutionary mechanism that becomes maladaptive in the context of modern high-fat diets.

The Pathophysiological Cascade

Acute dietary fat overload elevates insulin resistance via a well-characterised cellular cascade:

1. Lipid accumulation in myocytes: Diacylglycerol and ceramides activate protein kinase C.
2. IRS-1 serine phosphorylation: Blocks the normal insulin receptor signalling pathway.
3. Disrupted GLUT4 translocation: Glucose transport channels fail to migrate to the cell membrane.
4. Hepatic insulin resistance: The liver overproduces glucose, worsening hepatic steatosis.
5. Pancreatic lipotoxicity: Fat infiltration into the pancreas degrades beta-cell function.

In the presence of continuous caloric surplus, this muscle-level resistance redirects fat into non-adipose organs: first into the liver, and subsequently into the pancreas—the defining trigger for clinical diabetes.

Imaging Confirmation

Spectroscopic imaging visually confirms this process: healthy participants receiving a standardised lipid infusion showed marked increases in intramyocellular lipid droplets within 2–3 hours, alongside a 40–60% reduction in insulin-stimulated glucose disposal.

How Much Weight Loss Is Needed for Diabetes Remission?

Large-scale clinical trial data demonstrates a direct dose-response relationship between total weight loss and diabetes remission in individuals with an average disease duration of three years:

Evidence-Based Weight Loss Targets

A sustained weight loss of approximately 13 kg allows the majority of recently diagnosed individuals to reverse type 2 diabetes. Whilst structured therapeutic fasting can achieve this weight reduction, long-term weight maintenance remains the essential requirement.

The landmark UK DiRECT trial (Diabetes Remission Clinical Trial) provided conclusive real-world evidence: 298 patients with type 2 diabetes underwent an intensive 12-month primary care lifestyle programme, yielding clear remission thresholds.

Comparing Approaches: Finding the Best Intermittent Fasting for Diabetics

Different dietary strategies yield distinct weight loss and remission outcomes:

The Crucial Factor: Weight Maintenance

Clinical evidence is definitive: if lost weight is regained, type 2 diabetes almost invariably returns. Five-year follow-up studies reveal that 60–70% of individuals who achieved remission through weight loss relapse if they regain more than half of the weight they lost.

Achieving permanent remission requires long-term lifestyle changes rather than temporary crash dieting. The National Weight Control Registry highlights the consistent habits of over 10,000 individuals who have maintained a weight reduction of at least 13 kg for more than one year:

• 98% permanently modified their nutritional intake
• 94% increased everyday physical activity
• 78% eat breakfast daily
• 75% weigh themselves at least once a week
• 62% watch fewer than 10 hours of television per week
• 90% engage in an average of 1 hour of physical exercise daily

Intermittent Fasting for Diabetes vs Medication: Which Is More Effective?

The rediscovery of a fundamental principle: once the initial euphoria surrounding medicine’s “greatest miracle” — the discovery of insulin in 1921 — began to fade, forward-thinking clinicians recognised an uncomfortable truth: for people with type 2 diabetes, insulin alone is insufficient to prevent devastating long-term complications such as kidney failure, blindness, strokes and amputations.

The Insulin Paradox

Whilst insulin undoubtedly saves lives, in type 2 diabetes it often triggers a downward spiral: weight gain worsens insulin resistance, necessitating higher doses, which in turn drive further weight gain. Studies show that people with type 2 diabetes gain an average of 3–9 kg on insulin therapy — with a corresponding deterioration in glycaemic control.

A Paradigm Shift in Diabetes Care

As Elliott Joslin, one of the most renowned pioneers of diabetes treatment, prophetically argued back in 1923: “Self-discipline in diet and exercise should remain the chief factor in diabetes control, as it was before the insulin era.” His warning against “insulin dependency” proved remarkably visionary.

Modern diabetologists echo Joslin’s intuition: “We haven’t defeated diabetes; we have simply turned it into a chronic condition,” notes Professor Roy Taylor of Newcastle University. “True healing requires tackling the root causes, not merely managing symptoms.”

Comparing Treatment Approaches: Does Fasting Help with Diabetes?

A systematic analysis of the evidence reveals dramatic differences between intermittent fasting for diabetes and conventional drug therapy:

The Superior Efficacy of Fasting with Diabetes Type 2

The figures speak for themselves: no pharmaceutical drug comes close to matching the remission rates achieved through structured fasting. Crucially, fasting addresses the underlying root causes, whereas medications primarily manage symptoms.

Furthermore, fasting can exert therapeutic benefits on pre-existing diabetes-related complications:

• Diabetic nephropathy: Fasting can improve kidney function (eGFR increase of 10–15%)
• Diabetic retinopathy: Disease progression can be slowed
• Diabetic neuropathy: Symptom relief in 40–60% of patients
• Non-alcoholic fatty liver disease (hepatic steatosis): Complete reversal is possible
• Cardiovascular risk factors: Marked improvement across all parameters

The Limitations of Pharmacotherapy

Despite decades of drug development and billions invested in research, the inconvenient truth remains: no diabetes medication can halt the natural progression of the disease. The landmark UKPDS study involving 5,102 participants over 20 years demonstrated that even “optimal” drug therapy fails to prevent the progressive deterioration of beta-cell function.

Professor Jay Skyler of the University of Miami puts it succinctly: “We treat type 2 diabetes as if it were an insulin deficiency, when in reality it is driven by insulin resistance. It is like trying to fix a flooded basement by pumping in more water.”

Scientific References

• Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice. 2018;138:271-81.
• Guelpa G. Starvation and Purgation in the relief of disease. BMJ. 1910;2.
• Emerson H. Sweetness is Death. The Survey. October 1924:23-5.
• Tatar E, Karan C, Kircelli F. The dilemma of subclinical hypothyroidism and renal complications in Type 2 diabetes. Diabetic Medicine. 2016;33(1):135.
• Marble A. John Rollo. Diabetes. 1956;5(4):325-327.
• Allen FM, Frederick M, Stillman E, Fitz R. Total Dietary Regulation in the Treatment of Diabetes. New York, The Rockefeller Institute for Medical Research; 1919.
• Gacquin M. Historical perspectives of dietary recommendations for diabetes. In: Goff L, Dyson P, eds. Advanced Nutrition and Dietetics in Diabetes. Chichester, UK: John Wiley & Sons, Ltd; 2015:13-21.
• FREDERICK MADISON ALLEN 1879-1964. Metab Clin Exp. 1964;13:383-5.
• Allen F. Studies concerning diabetes. JAMA. 1914;63:939-43.
• Allen F. Prolonged fasting in diabetes. Amer J Med Sci. 1915;150:480-5.
• Bachmann OP, Dahl DB, Brechtel K, et al. Effects of Intravenous and Dietary Lipid Challenge on Intramyocellular Lipid Content and the Relation With Insulin Sensitivity in Humans. Diabetes. 2001;50(11):2579-84.
• Parry S, Woods R, Hodson L, Hulston C. A Single Day of Excessive Dietary Fat Intake Reduces Whole-Body Insulin Sensitivity: The Metabolic Consequence of Binge Eating. Nutrients. 2017;9(8):818.
• Nowotny B, Zahiragic L, Krog D, et al. Mechanisms Underlying the Onset of Oral Lipid-Induced Skeletal Muscle Insulin Resistance in Humans. Diabetes. 2013;62(7):2240-8.
• Hernández EÁ, Kahl S, Seelig A, et al. Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance. J Clin Invest. 2017;127(2):695-708.
• Taylor R. Calorie restriction for long-term remission of type 2 diabetes. Clin Med (Lond). 2019;19(1):37-42.
• Taylor R. Calorie restriction and reversal of type 2 diabetes. Expert Rev Endocrinol Metab. 2016;11(6):521-8.
• Lara-Castro C, Newcomer BR, Rowell J, et al. Effects of short-term very low-calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects. Metabolism. 2008;57(1):1-8.
• Taylor R, Barnes AC. Translating aetiological insight into sustainable management of type 2 diabetes. Diabetologia. 2018;61(2):273-83.
• Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-51.
• Taylor R, Barnes AC. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one. Diabet Med. 2019;36(3):308-15.
• O’Donnell S. Changing social and scientific discourses on type 2 diabetes between 1800 and 1950: a socio-historical analysis. Sociol Health Illn. 2015;37(7):1102-21.

Redaktion

+ postsBio ⮌

This author does not have any more posts